Back to search results

Xerava Prophylaxis for Hematological Malignancy Patients with Prolonged Neutropenia

This study is looking at whether the antibiotic Eravacycline (brand name Xerava) can help prevent infections in people with blood cancers (hematological malignancy) who are undergoing chemotherapy or stem cell transplants. These treatments can lead to a low white blood cell count (neutropenia), making patients very vulnerable to infections. Eravacycline is being tested to see if it can reduce the number of serious infections that occur. You might be able to join if you are an adult receiving certain types of chemotherapy for acute leukemia or preparing for a stem cell transplant, and meet specific liver function requirements. The study aims to see how many breakthrough infections happen while patients are taking Eravacycline. The current recruitment status is unclear.

Study design
This study is an interventional study planning to enroll 55 participants. The phase of the study is not specified.
What's involved
You would receive Eravacycline for up to 21 days, or until your white blood cell count recovers, you develop a fever, get an infection, or experience significant side effects.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, incidence of breakthrough infections, is measured for up to 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05537896

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
PHASE2Ages 18+InterventionalTreatment
West Virginia University
~55 participants
Updated 2026-04-16 on ClinicalTrials.gov
What's tested:Eravacycline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Documented Breakthrough Infections
Measured over Up to 21 days

Conditions

Hematological Malignancy
Neutropenia

Explore related trials

Acute LeukemiaHematopoietic Cell Transplantation

Where it's being run

1 sites across 1 states
West Virginia1

Study leadership

  • Aaron Cumpston, PharmD, BCOP · PRINCIPAL_INVESTIGATOR · West Virginia University

Who to contact

Aaron Cumpston, PharmD, BCOP
[email protected]
3045984000 · ext. 73350
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients receiving induction chemotherapy for treatment of acute leukemia or receiving preparative regimen for HSCT
Patient must provide informed consent.
Bilirubin ≤ 3 x the ULN and AST/ALT ≤ 5 x ULN

Exclusion

Uncontrolled bacterial, viral or fungal infection at the time of study enrollment.
Urinary tract infection receiving active treatment
Acute pancreatitis (not necessary to work-up unless symptomatic)
History of known hypersensitivity to eravacycline, tetracycline, doxycycline, minocycline, tigecycline, sarecycline, oxytetracycline, or omadacycline
Pseudomonas infection within 30 days prior to study enrollment
Receiving strong inhibitors or inducers of cytochrome P450 3A4 will be excluded from the study (see Appendix B for complete list of medications)
Pregnant or lactating women

What this trial measures

  • Incidence of Documented Breakthrough InfectionsUp to 21 days

    Number of Incidences documented that subjects had a confirmed breakthrough infection.